Article

Potentially Effective Treatment for Hepatocellular Carcinoma

Liver cancer cells died when the AURKA-MYC interaction was inhibited.

Researchers in a recent study found a new molecular mechanism that can inhibit the growth of hepatocellular carcinoma in humans and mice.

It was discovered that in liver cancers such as hepatocellular carcinoma where the protein p53 is disturbed or inhibited, the interaction between Aurora kinase A (AURKA) and MYC proteins are crucial. Inhibiting the AURKA protein with drug molecules stops this interaction and causes cancer cells to die, according to the study published in Nature Medicine.

Researchers analyzed the interaction between the AURKA and MYC proteins through computer-aided molecular modeling, which also revealed which drugs inhibited the interactions and which did not.

Through targeting the AURKA protein, it could potentially prevent the growth of p53-altered liver cancer and be used to develop new treatments for this cancer, the study concluded.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards